Investment
Features
FeesSafety
Academy
More
Pluang+

Syndax's Revuforj named one of TIME's Best Inventions of 2026 for treating acute leukemia.

Market News
15 Oct 2026
GlobeNewsWire
View Source
Bullish
Syndax's Revuforj named one of TIME's Best Inventions of 2026 for treating acute leukemia.

Syndax Pharmaceuticals announced that Revuforj (revumenib), its first-in-class menin inhibitor for treating relapsed or refractory acute leukemia, was selected by TIME as one of the Best Inventions of 2026 in the Medical and Healthcare category. Approved by the FDA for adults and children with specific genetic mutations in acute leukemia, Revuforj addresses aggressive forms of the disease with limited treatment options. The drug's recognition highlights its originality and impact in cancer care, with ongoing trials exploring broader uses. Safety warnings include risks of differentiation syndrome and heart-related side effects, emphasizing careful patient monitoring.

Syndax’s Revuforj® (revumenib) was named to TIME’s Best Inventions of 2026 list. For readers following the health sector, here is Pluang's market snapshot as of Oct 16, 2026 03:21 WIB: Of 150 priced Health-sector US stocks tradable on Pluang, 128 rose and 21 fell today. Top movers include RXRX (Recursion Pharmaceuticals Inc) at USD 4.16 with a 1-day change of +11.23% and typical hold time of 21 days, MRVI (Maravai LifeSciences Holdings Inc. Class A Common Stock) at USD 7.10 with +8.40% change and a typical hold time of 1 day, and ABEO (Abeona Therapeutics Inc) at USD 4.67 with +7.11% change and a typical hold time of 25 days.

More News

HDFC Bank to report earnings Oct 17; faces class action lawsuit over shares sold 2023-2026

HDFC Bank to report earnings Oct 17; faces class action lawsuit over shares sold 2023-2026

HDFC Bank is set to announce its quarterly earnings on October 17, 2026, with analysts expecting $0.40 earnings per share and $4.92 billion in revenue. The bank's valuation shows a trailing earnings multiple of 14.45x and a debt-to-equity ratio of 0....

Company Fundamentals
Neutral
24 minutes ago
Kohl's insider sells 18,352 shares amid mixed market views on stock's future.

Kohl's insider sells 18,352 shares amid mixed market views on stock's future.

Kohl's Chief Legal and Corporate Affairs Officer Jennifer J. Kent sold 18,352 shares for $403,744 on October 15, 2026, reducing her stake to 211,512 shares. Market opinions on Kohl's stock are divided, with some analysts expecting a decline while oth...

Market News
Neutral
1 hour ago
ManpowerGroup posts mixed Q3 results and announces new CEO for 2027

ManpowerGroup posts mixed Q3 results and announces new CEO for 2027

ManpowerGroup reported Q3 2026 revenue of $4.84 billion, slightly below estimates, with adjusted earnings per share at $1.01 matching expectations. Revenue grew 4% year-over-year, driven by strong U.S. Manpower and improving Experis segments. The com...

Company Fundamentals
Neutral
1 hour ago
Copper explorers in British Columbia use electrical surveys to identify promising drill targets amid rising copper prices.

Copper explorers in British Columbia use electrical surveys to identify promising drill targets amid rising copper prices.

Copper exploration in British Columbia is increasingly relying on induced polarization (IP) geophysical surveys, which measure electrical chargeability and resistivity in rocks to identify sulphide mineralization associated with copper deposits. Gold...

Market News
Bullish
1 hour ago
S&P 500 rises 30.6% in first 20 months of Trump's second term, nearing first term gains.

S&P 500 rises 30.6% in first 20 months of Trump's second term, nearing first term gains.

The S&P 500 index has increased by 30.6% during the first 20 months of Donald Trump's second presidential term, slightly surpassing the 28.5% gain recorded in the same period of his first term. This comparison is significant for investors as it provi...

Market News
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App